Medication Development for Treatment of Alcoholism

治疗酒精中毒的药物开发

• 批准号: 7547590
• 负责人: Robert A Harris
• 金额: $ 84.19万
• 依托单位: UNIVERSITY OF TEXAS AT AUSTIN
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7547590
• 关键词: Medication; Development; Treatment; Alcoholism

DESCRIPTION (provided by applicant): This three-year funding proposal for a P20 Center provides a new paradigm for medication development for the treatment of alcoholism by bringing experienced alcohol researchers together with experts in chemistry, proteomics, gene delivery and Drosophila genetics who are new to the alcohol field. The goal is to develop the technologies and collaborations necessary to define new targets for medication development and translate our knowledge of alcohol targets into selective ligands. The Center consists of an Administrative Core (Adron Harris, PI and Center Director), target identification by neuron-specific transcriptomics (Igor Ponomarev, PI), target identification by proteomics (Dayne Mayfield, PI), ligand selection by high throughput screening (John Mihic, PI), and an Animal Core (Yuri Blednov, PI) to provide mice and behavioral testing to the projects. In addition, we propose two Pilot Projects (two years in duration) to develop technology to test the biological importance of new targets. One will provide tools to deliver inhibitory RNAs (RNAi) to the brain (Maria Croyle, PI) and another will develop knock-in Drosophila carrying mutations in target genes (Nigel Atkinson, PI). The Center has both internal and external advisory boards, providing expert guidance from scientists with a wide range of expertise. A key aim is to provide the collaborations and infrastructure necessary for a future P50 application which will focus new researchers and new technologies on medication development for alcohol dependence.

描述（由申请人提供）：P20中心的这项为期三年的资金建议为治疗酒精中毒的新范式提供了一种新的范式，通过将经验丰富的酒精研究人员与化学，蛋白质组学，基因递送和果蝇遗传学专家聚集在一起，这些研究人员是酒精领域的新手。目的是开发确定药物开发的新目标所需的技术和协作，并将我们对酒精靶标的知识转化为选择性配体。 The Center consists of an Administrative Core (Adron Harris, PI and Center Director), target identification by neuron-specific transcriptomics (Igor Ponomarev, PI), target identification by proteomics (Dayne Mayfield, PI), ligand selection by high throughput screening (John Mihic, PI), and an Animal Core (Yuri Blednov, PI) to provide mice and behavioral testing to the projects.此外，我们提出了两个试点项目（持续两年）来开发技术来测试新目标的生物学重要性。一种将提供工具，以将抑制性RNA（RNAi）传递到大脑（Maria Croyle，PI），另一个将在靶基因（Nigel Atkinson，pi）中发展出果蝇的敲门果蝇。该中心具有内部和外部咨询委员会，为科学家提供了广泛专业知识的专家指导。一个关键目的是提供未来P50应用所需的合作和基础设施，该应用将把新的研究人员和新技术集中于酒精依赖的药物开发上。